Skip to main content
SHANGHAI MICROPORT EP MEDTECH CO., LTD. logo

SHANGHAI MICROPORT EP MEDTECH CO., LTD. — Investor Relations & Filings

Ticker · 688351 ISIN · CNE100005PG9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2023-03-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688351

About SHANGHAI MICROPORT EP MEDTECH CO., LTD.

https://www.everpace.com/

SHANGHAI MICROPORT EP MEDTECH CO., LTD. focuses on the research, development, and commercialization of medical devices for cardiac electrophysiology. The company provides a comprehensive suite of products for the diagnosis and treatment of cardiac arrhythmias, including 3D cardiac mapping systems, diagnostic catheters, and radiofrequency ablation catheters. Its core technology, the Columbus 3D EP Navigation System, enables precise localization and visualization of catheters within the heart. The product line also encompasses irrigation pumps and ablation generators designed to support minimally invasive procedures. The company aims to deliver integrated solutions that improve clinical outcomes for patients with rhythm disorders through advanced mapping and therapeutic technologies.

Recent filings

Filing Released Lang Actions
第三届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the second meeting of the third Supervisory Board of Shanghai MicroPort EP MedTech Co., Ltd. It includes multiple agenda items such as approval of the 2022 Supervisory Board work report, 2022 annual report and its summary, internal control self-assessment report, financial statements, fundraising usage report, profit distribution plan, related party transactions, asset purchase, remuneration for supervisors, and purchase of liability insurance for directors and officers. The document references the 2022 annual report and other reports but does not contain the full annual report itself; instead, it states that the full reports are published on the Shanghai Stock Exchange website. The document is 3285 characters long, which is relatively short and mainly serves as a meeting resolution announcement and summary of approvals, not the full financial report. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement of supervisory board meeting resolutions and related approvals, not the full Annual Report (10-K) or other detailed reports themselves.
2023-03-28 Chinese
独立董事关于第三届董事会第二次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various board meeting proposals, including internal control self-evaluation, profit distribution, related party transactions, asset purchase, director and senior management remuneration, and insurance for directors and officers. It references compliance with company articles, stock exchange rules, and internal control regulations. The document is not a full financial report but rather a formal opinion related to board meeting agenda items. It does not contain financial statements or detailed financial analysis. The content aligns with Board/Management Information (MANG) as it concerns board meeting proposals and related governance matters.
2023-03-28 Chinese
独立董事关于公司对外担保情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the year 2022. It references regulatory requirements from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content is a formal attestation that no external guarantees occurred during the reporting period. The document is short (588 characters) and primarily a certification or attestation by independent directors rather than a full report or announcement of financial results. It does not contain financial data or detailed analysis but is a regulatory compliance statement. Therefore, it fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure that does not fit other specific categories.
2023-03-28 Chinese
关于上海微创电生理医疗科技股份有限公司2022年度募集资金存放和使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放和使用情况专项核查报告" which translates to "Annual Special Verification Report on the Storage and Use of Raised Funds." It is issued by the sponsor institution 华泰联合证券有限责任公司 regarding the 2022 fiscal year. The content details the management, storage, and usage of funds raised from a public stock issuance, including bank accounts, balances, usage against planned projects, and compliance with regulatory requirements. It also includes an auditor's verification opinion on the raised funds usage and storage. This type of document is a specialized audit or verification report focusing on the use of raised capital, not a full annual report or earnings release. It is not a simple announcement or certification but a detailed audit-related report. Therefore, it fits best under the category Audit Report / Information (AR). The document length (6493 characters) supports it being a full report rather than a brief announcement. FY 2022
2023-03-28 Chinese
关于上海微创电生理医疗科技股份有限公司拟购买资产暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding a proposed asset purchase and related party transaction by Shanghai MicroPort EP MedTech Co., Ltd. It includes descriptions of the transaction, related parties, financial data, legal compliance, board and independent director approvals, and the sponsor's conclusion. The document references regulatory rules and company bylaws, and it is a formal verification or due diligence report rather than a financial report or announcement. It is not an annual or interim report, earnings release, or capital update. It is not a simple announcement or certification but a comprehensive verification opinion related to a specific transaction. This fits the category of Audit Report / Information (AR), which includes standalone audit or verification reports and related regulatory compliance information excluding full annual reports. H1 2022
2023-03-28 Chinese
关于2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai MicroPort EP MedTech Co., Ltd. regarding the expected related party transactions for the year 2023. It details the nature, amounts, and parties involved in these related party transactions, including board approvals, independent director opinions, and audit committee opinions. The document does not contain financial statements or comprehensive financial performance data but rather focuses on disclosure of expected related party transactions and compliance with regulatory requirements. It is not an annual report, interim report, earnings release, or audit report. It is also not a proxy statement or voting results announcement. The document is a regulatory announcement about expected related party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure and does not constitute a full financial report or other specific filing type.
2023-03-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.